“Global High Intensity Focused Ultrasound Market to reach a market value of USD 1.9 Billion by 2031 growing at a CAGR of 7.1%”
The Global High Intensity Focused Ultrasound Market size is expected to reach $1.9 billion by 2031, rising at a market growth of 7.1% CAGR during the forecast period.
HIFU is a uterus-preserving procedure, which is important for patients who wish to retain their uterus for future pregnancies. This aspect of HIFU makes it a preferred option for women who want to avoid hysterectomy, which involves the removal of the uterus. Thus, the uterine fibroids segment attained 19% revenue share in the market in 2023. HIFU is typically performed as an outpatient, meaning patients do not need to stay overnight in a hospital. This convenience adds to its appeal and makes it a more accessible option for many.
Chronic diseases like cancer are becoming more prevalent worldwide, with increasing rates of prostate cancer, liver cancer, and other solid tumours. HIFU has been established as an effective non-invasive treatment option for certain types of cancer, such as prostate cancer, where it is used to destroy cancerous tissues without the need for surgery. As per the WHO, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. Hence, the increasing prevalence of chronic diseases drives the market’s growth.
Patients increasingly seek less invasive treatments with fewer risks and shorter recovery times. Traditional surgical procedures often involve incisions, anaesthesia, and extended hospital stays, which can be daunting for many patients. In contrast, HIFU offers a non-invasive alternative using focused ultrasound waves to target and treat tissues without incisions. This appeal of a less invasive treatment option drives patient preference toward HIFU, increasing its adoption. In conclusion, the growing preference for non-invasive procedures propels the market’s growth.
However, HIFU equipment is sophisticated and technologically advanced, which results in high initial capital costs. The expense of purchasing, installing, and setting up HIFU systems can be prohibitive, particularly for smaller healthcare facilities or those in developing regions. This high upfront investment can deter healthcare providers from adopting HIFU technology. The maintenance of HIFU equipment requires specialized service and regular upgrades to ensure optimal performance. These ongoing costs add to the total expenditure of operating HIFU systems. In conclusion, the high cost of equipment and procedures is hampering the market’s growth.
Based on application, the market is divided into uterine fibroids, prostate cancer, essential tremor, dermatology, breast cancer, glaucoma, back pain, facetogenic, and others. In 2023, the dermatology segment garnered 20% revenue share in the market. HIFU is effective for non-surgical face lifting and tightening, which addresses common dermatological concerns such as sagging skin and wrinkles. It stimulates collagen production, leading to skin tightening and rejuvenation, which is particularly appealing in the cosmetic dermatology market.
By end use, the market is divided into hospitals, imaging centers, and others. The imaging centres segment procured 33% revenue share in the market in 2023. Imaging centres specialize in diagnostic imaging and interventional procedures, making them well-suited for performing HIFU. The expertise and focus on imaging in these centres enhance the quality of HIFU treatments and ensure accurate targeting. Imaging centres often provide a more accessible and convenient location for patients than hospitals.
Free Valuable Insights: Global High Intensity Focused Ultrasound Market size to reach USD 1.9 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 38% revenue share in the market in 2023. North America, particularly the United States and Canada, has a well-developed healthcare infrastructure with access to cutting-edge medical technologies and facilities. This infrastructure supports the adoption and use of advanced treatments like HIFU. The prevalence of conditions that HIFU can treat, such as uterine fibroids, prostate cancer, and certain types of tumours, is relatively high in North America. This drives the demand for effective treatment options.
Report Attribute | Details |
---|---|
Market size value in 2023 | USD 1.1 Billion |
Market size forecast in 2031 | USD 1.9 Billion |
Base Year | 2023 |
Historical Period | 2020 to 2022 |
Forecast Period | 2024 to 2031 |
Revenue Growth Rate | CAGR of 7.1% from 2024 to 2031 |
Number of Pages | 178 |
Number of Tables | 308 |
Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
Segments covered | End Use, Application, Region |
Country scope |
|
Companies Included | EDAP TMS S.A, Sonablate Corp., Verasonics, Inc., ALPINION MEDICAL SYSTEMS Co., Ltd., Theraclion, Lynton Lasers Ltd, ULTRAISER, PROFOUND MEDICAL CORP. |
By End Use
By Application
By Geography
This Market size is expected to reach $1.9 billion by 2031.
Growing Preference for Non-Invasive Procedures are driving the Market in coming years, however, High Cost of Equipment and Procedures restraints the growth of the Market.
EDAP TMS S.A, Sonablate Corp., Verasonics, Inc., ALPINION MEDICAL SYSTEMS Co., Ltd., Theraclion, Lynton Lasers Ltd, ULTRAISER, PROFOUND MEDICAL CORP.
The expected CAGR of this Market is 7.1% from 2024 to 2031.
The Hospital segment is leading the Market by End Use in 2023; thereby, achieving a market value of $684.8 million by 2031.
The North America region dominated the Market by Region in 2023; thereby, achieving a market value of $681.9 million by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.